Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Gemcitabine as Adjuvant Treatment After Resection of Intrahepatic Cholangiocarcinoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

8 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-09-05

Study Completion Date

2020-09-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a Phase I study, which means we want to find out what effects, good and/or bad, this combination of drugs may have on the patient and the liver cancer at different dose levels. All patients will have an operation to remove tumors in the liver and may have a pump placed in their abdomen.

On this study, both drugs given have been used in other patients for treatment of cholangiocarcinoma and other gastrointestinal cancers. Both drugs are approved by the food and drug administration (FDA) for treatment of liver cancer, but the two drugs have only been combined in a few patients.

That means that in this trial we also want to find out if this combination is safe.

The study will also evaluate if this treatment works in delaying or stopping the cancer from coming back after surgery.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Hepatic Arterial Infusion in Treating Patients With Locally Advanced, Non-Metastatic Cholangiocarcinoma

NCT01525069

Cholangiocarcinoma Liver Neoplasms

TERMINATED PHASE1

A Phase II Study of Continuous Hepatic Arterial Infusion With Floxuridine (FUDR) and Dexamethasone (DEX) in Patients With Unresectable Primary Hepatic Malignancy

NCT00587067

Hepatic Cancer

COMPLETED PHASE2

Hepatic Artery Infusion With FOLFOX in Liver Metastasis From Breast Cancer

NCT01937507

Metastatic Breast Cancer

TERMINATED PHASE2

Hepatic Artery Infusion Pump for NPC Liver Metastases

NCT03876574

Nasopharyngeal Carcinoma Neoplasm Metastasis Liver

COMPLETED PHASE1

Study of Safety/Feasibility of a Hybrid Model of Tertiary and Community Delivery of Hepatic Artery Infusion Chemotherapy

NCT07201519

Colorectal Cancer Metastatic Intrahepatic Cholangiocarcinoma

NOT_YET_RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Intrahepatic Cholangiocarcinoma Peripheral Cholangiocarcinoma Cholangiolar Carcinoma Cholangiocellular Carcinoma) (ICC)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

HAI with FLOXURIDINE & DEXAMETHASONE & GEMCITABINE

This is an open-label single arm study. multi-institution phase I dose escalating trial of adjuvant HAIP FUDR and Gemcitabine chemotherapy after curative resection of ICC. Hepatectomy with or without bile duct reconstruction and pump placement are performed. The patients will start therapy 4 weeks postoperatively. They will receive HAI FUDR/Dex and systemic gemcitabine in the following dose escalation levels of gemcitabine. The dose of HAI FUDR will be fixed. A classic 3+3 cohort dose escalation scheme will be used to identify the MTD of the combination.

Level 1: Systemic gemcitabine 650mg/m\^2 Day 1 and 15 and HAI FUDR/Dex 0.12mg/kg/day Day 1-14 Level 2.Systemic gemcitabine 800mg/m\^2 Day 1 and 15 HAI FUDR/Dex 0.12 mg/kg/day Day 1-14 Level 3. Systemic gemcitabine 1000mg/m\^2 Day 1 and 15 HAI FUDR/Dex 0.12 mg/kg/day Day 1-14

Group Type EXPERIMENTAL

Liver resection and placement of hepatic artery infusion pump

Intervention Type PROCEDURE

FLOXURIDINE

Intervention Type DRUG

DEXAMETHASONE

Intervention Type DRUG

GEMCITABINE

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Liver resection and placement of hepatic artery infusion pump

Intervention Type PROCEDURE

FLOXURIDINE

Intervention Type DRUG

DEXAMETHASONE

Intervention Type DRUG

GEMCITABINE

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically confirmed intrahepatic cholangiocarcinoma (also variously reported as peripheral cholangiocarcinoma, cholangiolar carcinoma or cholangiocellular carcinoma) (ICC). Confirmation of the diagnosis must be made at MSKCC or at the participating institution prior to initiating protocol therapy.
* Technically resectable, single tumors of any size, tumors with satellite nodules within 2 cm of the primary tumor that are resectable. Limited and resectable multi-focal disease (less than 4 tumors technically resectable).
* Patients with elevated liver function tests including jaundiced patients (due to tumor) can be selectively operated on without resolution of jaundice preoperatively according to the judgment of the operating surgeon
* Patients must have a KPS \> 80% and be considered candidates for general anesthesia, hepatic resection and hepatic artery pump placement.
* Laboratory values within 14 days before registration must be:
* Serum albumin must be \>2.5 g/dl
* Creatinine must be \< 1.8 mg/dL
* WBC must be \>3500 cells/mm3
* Platelet count must be \>100,000/mm3
* International normalized ratio (INR) must be less than 1.5 in patients not on Coumadin therapy
* Technically resectable, single tumors of any size, tumors with satellite nodules within 2 cm of the primary tumor that are resectable. Limited and resectable multi- focal disease (less than 4 tumors technically resectable).
* Patients with elevated liver function tests including jaundiced patients (due to tumor) can be selectively operated on without resolution of jaundice preoperatively according to the judgment of the operating surgeon
* Age \>18 years
* Patients must be able to understand and sign informed consent
* Prior chemotherapy is allowed

Exclusion Criteria

* Prior treatment with HAI chemotherapy
* Extrahepatic metastases including nodal disease
* Prior external beam radiation therapy to the liver
* Diagnosis of sclerosing cholangitis
* Diagnosis of Gilbert's disease
* Clinical ascites
* Hepatic encephalopathy
* Patients who have radiographic evidence of esophageal varices or history of variceal hemorrhage
* Patients with occlusion of the main portal vein or of the right and left portal branches
* Patients that have concurrent malignancies (except localized basal cell or squamous cell skin cancers)
* Female patients who are pregnant or lactating

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No